The United States Food and Drug Administration (USFDA) has inspected Eugia Unit-III, a Formulation manufacturing facility, of Eugia Pharma Specialities, a wholly owned subsidiary of Aurobindo Pharma, situated at Phase-III, TSIIC, EPIP, IDA, Pashamylaram, Patancheru Revenue Mandal, Sangareddy District, Telangana, from January 27, 2026 to February 06, 2026. The inspection had concluded with 11 observations.
FDA has now determined that the inspection classification of this facility is ‘official action indicated’ (OAI). The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
